Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Etelcalcetide (Parsabiv) vs Romiplostim (Nplate)
An educational, source-based comparison of Etelcalcetide (Parsabiv) and Romiplostim (Nplate) — how each peptide works, what it's researched for, and what to know before going deeper.
Calcimimetic peptide for secondary hyperparathyroidism on hemodialysis.
Synthetic D-amino-acid peptide that binds the calcium-sensing receptor on parathyroid chief cells, increasing its sensitivity to extracellular calcium and lowering PTH secretion.
- Secondary hyperparathyroidism in adults on chronic hemodialysis
- • FDA-approved.
- • Hypocalcemia common; monitor calcium and avoid in low corrected calcium.
Thrombopoietin-receptor peptibody for immune thrombocytopenia.
Peptibody (Fc-peptide fusion) containing TPO receptor-binding peptide domains that activate c-Mpl on megakaryocytes, stimulating platelet production without competing with endogenous TPO.
- Chronic immune thrombocytopenia (ITP)
- Pediatric ITP
- Hematopoietic syndrome of acute radiation
- • FDA-approved.
- • Reticulin fiber deposition in bone marrow; thrombosis risk with over-correction.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Etelcalcetide (Parsabiv) | Etelcalcetide vs cinacalcet | JAMA | 2017 | Non-inferior PTH reduction with IV administration. |
| Romiplostim (Nplate) | Romiplostim in chronic ITP | Lancet | 2008 | Sustained platelet responses vs placebo in splenectomized and non-splenectomized adults. |
Side-effect & safety grid
- FDA-approved.
- Hypocalcemia common; monitor calcium and avoid in low corrected calcium.
- FDA-approved.
- Reticulin fiber deposition in bone marrow; thrombosis risk with over-correction.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Etelcalcetide (Parsabiv) vs Romiplostim (Nplate) — Key differences
- Class: Etelcalcetide (Parsabiv) is classified as Calcium-Sensing Receptor Agonist · Endocrine, while Romiplostim (Nplate) is TPO Mimetic · Hematology.
- Primary research focus: Etelcalcetide (Parsabiv) — secondary hyperparathyroidism in adults on chronic hemodialysis; Romiplostim (Nplate) — chronic immune thrombocytopenia (itp).
- Tag: FDA-Approved · Endocrine vs FDA-Approved · Hematology.